Funding
Series B · Biotech

Leyden Laboratories raises €40m Series B for nasal-spray candidates

EIC Fund, Invest-NL, Gates Foundation and ClavystBio participated in the financing.

Updated Oct 16, 2026By RoundOS Funding desk

Leyden Laboratories raised €40 million in Series B financing on June 25. Participants included European Innovation Council Fund, Invest-NL, Gates Foundation and ClavystBio. The company develops antibody-based nasal sprays intended to prevent influenza and other respiratory-virus infections.

Funding history

Series B · This round€40M

Sources

  1. Leyden Laboratoriesprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related